In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

Another immunotherapy has been approved for use in urothelial cancer, the most common type of bladder cancer, in the United States. Avelumab (Bavencio, EMD Serono INc), which is a programmed cell ...

Avelumab is first drug approval for MCC Tom Judd had already been failed by chemotherapy for his metastatic MCC, but under the care of Nghiem and his colleagues, he survived long enough to enroll in ...

Avelumab is a type of immunotherapy, known as a checkpoint inhibitor, which blocks a protein called PD-L1 on the surface of tumour cells. When PD-L1 is active it helps cancers hide from the immune ...

Avelumab has been filed for use in patients ... Merck Inc and Pfizer had seemed like outsiders in the immunotherapy race just two years ago, when PD-1 inhibitors Merck’s Keytruda and BMS ...

The predictive role of TRAIL gene expression in immune checkpoint inhibitor (ICI)-treated patients (pts). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

An immunotherapy can also be combined with another therapy as a form of treatment, as seen in the two new studies. The avelumab-axitinib study involved 886 renal cell cancer patients. Among them ...

Treatment with pepinemab, an anti–semaphorin 4D antibody, and avelumab, a programmed death-ligand 1 (PD-L1) inhibitor, produced disease control rates of 59% in immunotherapy-resistant patients ...

With the FDA approval, avelumab becomes the first immunotherapy option for the treatment of metastatic MCC, a rare form of skin cancer, which until now was being treated only with chemotherapy.

A novel immunotherapy approach developed by Ludwig ... combining these CV1-producing T cells with cancer-targeting antibodies such as avelumab and cetuximab further improved the ability of ...